Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Advanced melanoma

Pembrolizumab is superior to ipilimumab

    • Dermatology and venereology
    • News
    • Oncology
    • RX
    • Studies
  • 3 minute read

There is news on the KEYNOTE-006 study evaluating pembrolizumab (Keytruda®) for the treatment of advanced melanoma. The study was terminated early after the defined endpoints consisting of progression-free and overall survival were met early. Specifically, pembrolizumab reduced mortality risk by more than 30% compared with ipilimumab.

Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1/-L2). By binding to the PD-1 receptor, it prevents suppression of the immune response that occurs through the PD-1 pathway and stimulates the immune system to fight cancer cells.

The Phase III trial, called KEYNOTE-006, used the compound to treat unresectable advanced malignant melanoma (stage III or IV) and compared it to ipilimumab (anti-CTLA-4). Thus, two immunotherapies targeting different immune checkpoint signaling pathways faced each other. The 834 participating patients had not undergone more than one prior systemic therapy. They received either pembrolizumab 10 mg/kg every two weeks (n=279), every three weeks (n=277), or four cycles of ipilimumab 3 mg/kg every three weeks (n=278).

Premature end

The study was stopped early at the end of March 2015. This was due to the following results presented at the annual meeting of the American Association for Cancer Research and published in the New England Journal of Medicine [1]:

  • One of the primary endpoints, progression-free survival (PFS), showed median values of 5.5 months (pembrolizumab every two weeks [a]), 4.1 months (every three weeks [b]), and 2.8 months (ipilimumab [c]). Overall, the risk of progression was significantly reduced by 42% with pembrolizumab compared with ipilimumab. At six months, the calculated PFS rates were 47.3% (a), 46,4% (b) resp. 26,5% (c).
  • The 1-year overall survival rate (also primary endpoint) was 74.1% (a), 68,4% (b) and 58.2 (c), which corresponds to a significant mortality risk reduction of 37% resp. 31% corresponds.
  • Secondary endpoints included overall response rate: it was 33.7% (a), 32,9% (b) and 11.9 (c); the difference from ipilimumab was significant for both pembrolizumab regimens. At the time of cutoff after an average of 7.9 months, response lasted in 89.4% (a), 96,7% (b) vs. 87.9 (c) of the patients.
  • The safety and efficacy profiles of the two pembrolizumab regimens tested were comparable. KEYNOTE-001 and -002 had already shown that the two regimens at 10 mg/kg were equally effective and safe as the currently approved 2 mg/kg dose every three weeks.
  • Overall, the safety profile of pembrolizumab was consistent with the SmPC: most common treatment-associated adverse events were fatigue, diarrhea, rash, and pruritus. Most common autoimmune or immune-associated side effects were hypo- and hyperthyroidism.
  • Grade three and four adverse events occurred less frequently with pembrolizumab than with ipilimumab (in 13.3% [a], 10.1% [b] vs. 19.9% [c] of patients). Treatment discontinuations occurred more frequently with ipilimumab.

Indication extension

“Ultimately, the goal of any cancer trial is to prolong life, which in KEYNOTE-006 was even associated with a reduction in severe side effects,” said Caroline Robert, MD, Paris, lead author of the published article. Currently, pembrolizumab is approved in the U.S. following progression on ipilimumab. Based on the compelling data from KEYNOTE-006, the manufacturer now plans to file for approval for first-line treatment in advanced melanoma by mid-year.

Source: MSD media release (April 19, 2015).

Literature:

  1. Robert C, et al: Pembrolizumab versus ipilimumab in advanced melanoma. NEJM April 19, 2015. DOI: 10.1056/NEJMoa1503093.

InFo ONCOLOGY & HEMATOLOGY 2015; 3(5): 7.

 

Autoren
  • Andreas Grossmann
Publikation
  • InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
  • Ipilimumamb
  • KEYNOTE
  • Melanoma
  • Pembrolizumab
Previous Article
  • Annual meeting of the SGAD

Gut, heart and hormones – do they influence the risk of depression?

  • Cardiology
  • Congress Reports
  • Endocrinology and Diabetology
  • Gastroenterology and Hepatology
  • Nutrition
  • Psychiatry and psychotherapy
  • RX
View Post
Next Article
  • New Rheumatism League campaign

How to prevent falls?

  • Geriatrics
  • Rheumatology
  • RX
View Post
You May Also Like
View Post
  • 5 min
  • Asthma in adults

When do pneumology specialists come into play?

    • RX
View Post
  • 10 min
  • Cutaneous lupus erythematosus

From diagnostic workup to successful treatment

    • Congress Reports
    • Dermatology and venereology
    • RX
    • Studies
View Post
  • 4 min
  • Guideline update

Dietary recommendations for Crohn’s disease and colitis

    • Education
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 4 min
  • Circadian rhythm during Ramadan

Disturbed sleep patterns lead to metabolic stress

    • Education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.